MDxHealth SA ADR (MDXH) Stock Forecast & Price Target
MDxHealth SA ADR · NASDAQ
$0.76-0.03 (-4.01%)
15-min delayed · Aug 26, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering MDxHealth SA ADR, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets range widely, $1.50 to $4.00 (about 2.7x), a sign of real disagreement on valuation. The average target of $2.83 sits 274% above the current $0.76. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.38 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Strong Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to MDxHealth SA ADR.
As of Aug, 3 of 3 firms rate MDXH a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
MDXH EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.10 – $-0.05 · 5 analysts · -55% YoY
Next period, 5 analysts expect MDxHealth SA ADR to earn $-0.08 a share (range $-0.10 – $-0.05), versus $-0.17 a year earlier. Full-year consensus is $-0.46, growing to $-0.38 the year after.
REVENUE · NEXT QUARTER
$26.3M
Range $24.9M – $27.3M · 5 analysts · +5% YoY
Revenue is expected to reach $26.3M (range $24.9M – $27.3M), +5.1% year-over-year. Full-year consensus is $96.1M, rising to $108.8M next year.
Top analysts covering MDxHealth SA ADR
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on MDXH.
#1
TF
Thomas Flaten
Lake Street · Rank #229
Buy
$3.00+296.1% to target
Overall win rate
40%
+ Follow
#2
Mark Massaro
BTIG
Buy
$4.00+428.1% to target
Coverage
—
+ Follow
#3
DB
Dan Brennan
TD Cowen
Buy
$1.50+98.0% to target
Coverage
—
+ Follow
MDXH stock forecast FAQ
What is MDXH's average 12-month price target?+
The 3 analysts with a live target average $2.83 for MDxHealth SA ADR over the next 12 months, ranging from a $4.00 high to a $1.50 low.
Is MDXH stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for MDXH?+
The Street-high target is $4.00 (BTIG), and the Street-low is $1.50 (TD Cowen). The average of all 3 active targets is $2.83.
How many Wall Street analysts cover MDXH?+
3 analysts have an active rating on MDxHealth SA ADR, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering MDXH?+
Among analysts who currently cover MDXH, Thomas Flaten of Lake Street has the strongest overall Quantellect track record (Rank #229). Their current call is Buy with a $3.00 target.
What is MDxHealth SA ADR's projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.10 – $-0.05) across 5 analysts. Full-year EPS is projected at $-0.46, rising to $-0.38 the following year.
How much revenue is MDxHealth SA ADR expected to report next quarter?+
Consensus revenue is $26.3M (range $24.9M – $27.3M). Full-year revenue is projected at $96.1M, growing to $108.8M next year.
Have analysts been upgrading or downgrading MDXH lately?+
As of Aug, 3 of 3 firms rate MDXH a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their MDXH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
